Expert Interview
Examining the potential of Sanofi's factor VIII replacement therapy, efanesoctocog alfa (BIVV001) in severe hemophilia A
Ticker(s): SNYA hematologist with experience treating hemophilia a
Please describe your background and practice setting
Added By: ben_adminHow many patients with hemophilia A do you currently manage?
Added By: ben_adminWhat is the current standard of care for Hemophila A?
Added By: ben_adminAre you familiar with efanesoctocog alfa?
Added By: ben_adminThe primary endpoint for this study was the median and mean annualized bleeding rates (ABR): Can you describe this endpoint and if you found the data significant?
Added By: ben_adminWhere do you see this treatment option fitting into your algorithm if it is approved?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Nov 22, 2022
- Call Time
- 03:00 PM EST
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
